Wellgistics Health Inc. shares surged in pre-market trading, climbing 27.5% to $4.03 in the first full pre-market session after the company executed a 1-for-50 reverse stock split that became effective at 12:01 a.m. ET on May 26, 2026. The corporate action sharply reduced the companys outstanding common stock and immediately altered the per-share price basis for the market.
The reverse split was explicitly implemented to lift the trading price per share and address a Nasdaq minimum bid price deficiency. The split cut outstanding common shares from roughly 125.7 million to about 2.5 million. Fractional shares were rounded up, and the company applied proportional adjustments to outstanding options, warrants, and convertible securities.
While the mechanical impact of the reverse split set the stage for a higher nominal share price, recent strategic developments added fuel to the intraday move. Wellgistics signed a fully binding term sheet with Datavault AI to create DelivMeds AI, a planned entity for which the Nasdaq ticker MEDS has been reserved. The transaction package described in the term sheet consists of three concurrent deals: an expanded PharmacyChain HaaS license, the acquisition of QOLPOM biometric and drone logistics intellectual property, and the purchase of a controlling interest in Tollo Health. The combined asset value tied to the planned transactions is expected to be approximately $4 billion.
Operationally, Wellgistics reported Q1 2026 results on May 19 that showed traction in its pharmacy business and a markedly smaller operating loss year-over-year. Pharmacy monthly revenue rose from about $0.1 million in November 2025 to $0.6 million in April 2026, and sequential quarterly revenue increased from $0.486 million to $0.929 million. On the profitability front, the companies net operating loss narrowed to $7.742 million in Q1 2026 from $32.430 million in the year-ago quarter.
Market conditions in U.S. equities were effectively neutral on the session that accompanied Wellgistics post-split trading, with the S&P 500 flat at +0.0%, the Dow Jones Industrial Average up +0.4%, and the Nasdaq Composite up +0.1%. Those readings indicate that macro market forces were neither a clear tailwind nor a drag on the stocks outsized pre-market move.
It is important to note the regulatory context behind the reverse split. Wellgistics had previously received notice from Nasdaq for failing to meet the minimum bid price requirement and was granted an initial 180-day compliance period. The reverse split is a direct response to that deficiency and represents a material step toward regaining compliance with Nasdaq listing standards.
Despite the positive elements that drove speculative demand, the company continues to disclose substantial doubt about its ability to continue as a going concern. Management has also acknowledged remaining Nasdaq bid-price and equity deficiencies that the reverse split alone may not fully resolve. These disclosures underscore that, although the split and strategic announcements have prompted renewed investor interest, significant operational and regulatory risks persist.
In summary, the pronounced pre-market gain in Wellgistics stock reflects the combined effect of a post-reverse-split repricing, the potential for improved Nasdaq listing status, and ambitious strategic announcements tied to the creation of DelivMeds AI and rising pharmacy revenue. Together, these factors have increased speculative appetite for WGRX shares, even as the company faces ongoing financial and compliance uncertainties.